Uses of GnRH Agonists

Catharine Garner, C Garner, Chris Garner, Garner C
Journal of obstetric, gynecologic, and neonatal nursing : JOGNN · 1994 · vol. 23(7) , pp. 563–570 · doi:10.1111/j.1552-6909.1994.tb01922.x · PMID:7996307 · W2069020429
review OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-27 ⓘ

This paper discusses the applications and therapeutic benefits of gonadotropin-releasing hormone (GnRH) agonists.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Gonadotropin-releasing hormone agonists are a relatively new class of drugs, which, when chronically administered, result in marked reductions in blood levels of testosterone and estrogen. These drugs include leuprolide acetate (Lupron); the first GnRH agonist to be approved in the United States, nafarelin acetate (Synarel); and goserelin acetate (Zoladex). Approved indications for these drugs, depending on the specific agent, include advanced prostate cancer, endometriosis, and precocious puberty. These and other investigational GnRH agonists are also being evaluated in many other diseases, including uterine fibroids, polycystic ovarian disease, breast cancer, fibrocystic breast disease, benign prostatic hypertrophy, and irritable bowel syndrome. Because of their therapeutic potential in many endocrinologic disorders, the GnRH agonists represent one of the most important advances in hormonal therapy in the past few decades. Thus, it appears likely that in the 1990s a greater number of patients will be receiving these agents. This article summarizes the application of GnRH agonist drugs in clinical practice, their side effects, and important information for patient use.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Breast Neoplasms Breast Neoplasms Child Endometriosis Endometriosis Female Fibrocystic Breast Disease Fibrocystic Breast Disease Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Leiomyoma Leiomyoma Male Ovulation Induction Patient Education as Topic Polycystic Ovary Syndrome Polycystic Ovary Syndrome Puberty, Precocious

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Cited by (3)

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:24.284338+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK